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Abstract Lipoprotein lipase (LPL) undergoes spontaneous inactivation via global unfolding and
this unfolding is prevented by GPIHBP1 (Mysling et al., 2016). We now show: (1) that ANGPTL4
inactivates LPL by catalyzing the unfolding of its hydrolase domain; (2) that binding to GPIHBP1
renders LPL largely refractory to this inhibition; and (3) that both the LU domain and the intrinsically
disordered acidic domain of GPIHBP1 are required for this protective effect. Genetic studies have
found that a common polymorphic variant in ANGPTL4 results in lower plasma triglyceride levels.
We now report: (1) that this ANGPTL4 variant is less efficient in catalyzing the unfolding of LPL; and
(2) that its Glu-to-Lys substitution destabilizes its N-terminal a-helix. Our work elucidates the
molecular basis for regulation of LPL activity by ANGPTL4, highlights the physiological relevance of
the inherent instability of LPL, and sheds light on the molecular defects in a clinically relevant
variant of ANGPTL4.
DOI: 10.7554/eLife.20958.001
Introduction
The intravascular hydrolysis of triglycerides in triglyceride-rich lipoproteins (TRLs) by lipoprotein
lipase (LPL) is an efficient mechanism for delivering lipid nutrients to vital tissues (e.g., heart, skeletal
muscle, adipose tissue). LPL is secreted into the interstitial spaces by myocytes and adipocytes but is
then shuttled to the capillary lumen by an endothelial transporter, glycosylphosphatidylinositol-
anchored high density lipoprotein–binding protein 1 (GPIHBP1) (Fong et al., 2016). This endothelial
cell LPL transporter is also required for the margination of TRLs along capillaries (Goulbourne et al.,
2014). Disruption of LPL transport by either genetic ablation of GPIHBP1 in mice (Beigneux et al.,
2007) or by loss-of-function missense mutations in humans leads to sustained elevations in plasma
triglyceride levels—a condition known as familial chylomicronemia (Ariza et al., 2016;
Beigneux et al., 2015, 2009b; Olivecrona et al., 2010; Plengpanich et al., 2014).
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Appropriate distribution of lipid nutrients to tissues is, however, not only controlled by the avail-
ability of LPL and GPIHBP1, but is also tightly regulated by endogenous protein inhibitors of LPL
activity (angiopoietin-like (ANGPTL) proteins 3, 4, and 8). Reciprocal regulation of ANGPTL4 expres-
sion in brown and white adipocytes with prolonged cold exposure results in high LPL activity in
brown adipocytes and ensures the delivery of lipid nutrients for adaptive thermogenesis (Dijk et al.,
2015). In the fed state, this balance is reversed, resulting in high LPL activity in white adipose tissue
and allowing replenishment of lipid stores in white adipose tissue. The relevance of these inhibitors
to LPL-mediated TRL processing in vivo is illustrated by lower plasma triglyceride levels with pharma-
cological inhibition or genetic ablation of ANGPTL3 or ANGPTL4 (Desai et al., 2007;
Gusarova et al., 2015; Ko¨ster et al., 2005). Additional evidence for their physiological importance
are provided by genome-wide association studies (GWAS), which showed that a polymorphic variant
of ANGPTL4, E40K (E15K in the mature protein) is associated with mild hypotriglyceridemia and
reduced risk of coronary artery disease (Dewey et al., 2016; Helgadottir et al., 2016;
Stitziel et al., 2016). Throughout this paper, we will use amino acid numbering starting at the amino
terminus of the mature proteins.
Although genetic and physiologic evidence emphasizes the importance of ANGPTL-mediated
regulation of LPL-activity, our understanding of the biochemical and structural basis for this inhibi-
tory activity remains incomplete. An early report suggested that the N-terminal coiled-coil domain
of ANGPTL4 catalyzed the conversion of LPL homodimers to inactive LPL monomers
(Sukonina et al., 2006). However, this conclusion has been challenged by a report suggesting that
ANGPTL4 inhibits LPL by a reversible and noncompetitive mechanism (Lafferty et al., 2013). Thus
far, this controversy is unsettled.
In the current study, we take advantage of hydrogen–deuterium exchange mass spectrometry
(HDX-MS) to probe the structural changes in LPL that accompany both spontaneous decay of LPL
activity and ANGPTL-mediated inhibition of LPL activity. Our data show that ANGPTL4 does in fact
catalyze the irreversible inactivation of LPL and does so by promoting unfolding of LPL´s hydrolase
domain. Notably, we also document that the polymorphic variant ANGPTL4E15K has a lower capacity
to inhibit LPL activity and lower capacity to catalyze the unfolding of LPL´s hydrolase domain, com-
pared with wild-type ANGPTL4. This reduced activity is associated with destabilization and coopera-
tive unfolding of the N-terminal a-helix in ANGPTL4, a region of ANGPTL4 that had previously been
implicated in LPL inhibition (Lee et al., 2009; Yau et al., 2009).
Results
Spontaneous unfolding of LPL is catalyzed by ANGPTL4
We previously showed that LPL irreversibly loses catalytic activity by undergoing a time- and temper-
ature-dependent global unfolding of its serine hydrolase domain (Mysling et al., 2016). In contrast,
the C-terminal lipid-binding domain of LPL remains stably folded. Since LPL activity in vivo is regu-
lated in an organ-specific manner by ANGPTL 3, 4, and 8 (Dijk et al., 2015; Dijk and Kersten,
2016; Wang et al., 2015, 2013a), we speculated that these proteins might catalyze the unfolding of
LPL´s hydrolase domain. To explore this possibility, we incubated 10 mM bovine LPL, either alone or
in the presence of 1 mM purified ANGPTL41–159, at 25˚C in 8.8 mM Na2HPO4, 0.7 mM HCOOH, and
150 mM NaCl, pH 6.9. The time-dependent unfolding of LPL´s hydrolase domain was probed by
changes in hydrogen–deuterium exchange profiles with short (10 s) exposures to D2O. Deuterium
exchange was quenched by lowering the pH, and the deuterium uptake into different regions of LPL
was assessed by on-line pepsin digestion and mass spectrometry (Mysling et al., 2016). This
approach provides an imprint of regional changes in protein stability within LPL under variable con-
ditions. Mass spectrometry revealed that 10 mM LPL undergoes a slow spontaneous transition into
an unfolded state during the selected incubation time interval (0–30 min), with 29% of the LPL being
unfolded after 30 min at 25˚C (Figure 1). The amount of LPL unfolding was quantified by the gradual
progression towards a bimodal signature in the isotope envelope for the ‘diagnostic’ peptic peptide
131–165 from LPL´s hydrolase domain – Figure 1A (Mysling et al., 2016). Quantitative assessment
of this distribution reveals that 7.0 ± 0.7% of LPL was in the unfolded state after 5 min. Adding 1 mM
ANGPTL41–159 to 10 mM LPL greatly accelerated the rate of LPL unfolding, with 60.3 ± 2.3% of the
LPL being unfolded after 5 min (Figure 1B). Even though the amount of ANGPTL41–159 added was
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Figure 1. Kinetics of spontaneous and ANGPTL4-mediated unfolding of LPL´s serine hydrolase domain. Unfolding of the hydrolase domain in LPL is
revealed by the bimodality in the isotope envelopes for the peptide 131–165, which contains two residues from LPL´s catalytic triad (Ser134 and Asp158).
Time-resolved isotope signatures of this diagnostic peptide are shown for 10 mM LPL incubated alone (panel A) or in the presence of 1 mM ANGPTL41–
159 (panel B). The butterfly plot in panel C compares the spontaneous and ANGPTL4-catalyzed unfolding of LPL at conditions where 10–15% (orange
curve) or 15–20% (black curve) bimodality for peptide 131–165 is observed. The deuterium uptakes were calculated from the average mass of the
bimodal isotope envelopes. The shaded gray area corresponds to the largest standard deviation in the data sets recorded for each peptide (triplicates).
Transparent red and cyan colors on the left assign these peptides to LPL´s N-terminal hydrolase domain (NTD) or its C-terminal lipid-binding domain
(CTD), respectively. The identities of the 92 peptic LPL peptides are found elsewhere (Mysling et al., 2016). Panel D shows the time-dependent
unfolding of 10 mM LPL either alone (~) or in the presence of ANGPTL41–159 (□) at 2, 1, 0.5, and 0.25 mM, as indicated by green, red, blue, and yellow
coloring, respectively. This value is calculated as the ratio between the bimodal isotope envelopes of the folded and unfolded proteins. Panel E shows
a homology model of LPL with the proposed head-to-tail homodimer formation indicated by the semitransparent LPL subunit (Kobayashi et al., 2002;
Wang et al., 2013b). The red color highlights the regions in LPL showing bimodality of isotope envelopes (i.e., unfolding) by HDX-MS.
DOI: 10.7554/eLife.20958.002
The following figure supplements are available for figure 1:
Figure 1 continued on next page
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substoichiometric relative to LPL (a molar ratio of 1:10), ANGPTL4 was responsible for unfold-
ing >50% of LPL molecules in 5 min. This noticeable amount of LPL unfolding by substoichiometric
amounts of ANGPTL4 constitutes a strong argument in favor of the catalytic nature of ANGPTL4-
mediated LPL inactivation (Sukonina et al., 2006). Because the kinetic profiles for LPL unfolding
with 1 mM ANGPTL41–159 suggested that substrate depletion occurred (Figure 1D), we also tested
the ability of lower amounts of ANGPTL4 (0.5 mM, 0.25 mM) to unfold LPL. Those studies provided
clear evidence for a dose-dependent inactivation of LPL by ANGPTL4 (Figure 1D). The lowest
ANGPTL4 concentration tested resulted in 74 ± 6% LPL unfolding after 30 min compared to a spon-
taneous unfolding of 28.6 ± 1.3% in the buffer lacking ANGPTL4. Even though ANGPTL41–159 was
present at a molar ratio of 1:40 (relative to LPL), it nevertheless resulted in the unfolding of 50% of
LPL molecules. From early time point measurements, where substrate depletion was negligible, we
estimate that the unfolding efficacy of our ANGPTL41–159 preparation was 1.6 ± 0.2 molecules of LPL
per ANGPTL4 molecule per min at 25˚C (Figure 1—figure supplement 1). When identical incuba-
tions of LPL and ANGPTL4 were analyzed for lipolytic activity with [3H]triolein, we found a similar
time- and dose-dependent inhibition of LPL catalytic activity by ANGPTL41–159 (Figure 1—figure
supplement 2).
To compare the conformational changes associated with spontaneous and ANGPTL4-catalyzed
inactivation of LPL, we examined the deuterium uptake values for all 92 peptic peptides recovered
from LPL. To standardize the alignment of these data, we selected conditions that led to uniform
and relatively low levels of bimodality in the ‘diagnostic’ peptide 131–165. By compiling all data
recorded for spontaneous and ANGPTL4-catalyzed unfolding, we generated two bins of data with
10–15% or 15–20% bimodality in the isotope envelopes for peptide 131–165. In comparing the deu-
terium uptake across all LPL peptides, we observed no differences in the pattern of deuterium
uptake into LPL molecules undergoing spontaneous or ANGPTL4-catalyzed unfolding (Figure 1C).
Of note, all peptides showing bimodality were confined to the serine hydrolase domain of LPL
(Figure 1E); none were in the C-terminal lipid-binding domain. Based on these data, we conclude
that different means of LPL inactivation are mirrored by similar conformational endpoints whether
they occur spontaneously or are catalyzed by ANGPTL4.
Several reports show that ANGPTL4 is prone to various degrees of oligomerization via intermo-
lecular disulfide bonds involving Cys51 and Cys55 in ANGPTL4´s N-terminal coiled-coil domain
(Ge et al., 2004a, 2004b; Yin et al., 2009). Our ANGPTL41–159 preparation also contained disul-
fide-linked oligomers, although they were predominantly in the form of dimers and comprised no
more than 10% of the protein preparation (Figure 1—figure supplement 3A). In monomeric
ANGPTL4, we find that Cys51 and Cys55 are connected by an intramolecular disulfide bond, as dem-
onstrated by masses of 3440.64 and 3442.64 Da for peptides corresponding to residues 45–77 in
ANGPTL41–159 before and after reduction with tris-(2-carboxyethyl) phosphine (TCEP) (Figure 1—fig-
ure supplement 3B and C). To exclude the possibility that a minor fraction of disulfide-linked
ANGPTL4 oligomers are responsible for all of ANGPTL4´s catalytic unfolding activity, we reduced
and alkylated the disulfide-bonds in ANGPTL4 and then compared the LPL unfolding capacity with
ANGPTL4 harboring intact disulfide bonds. As shown in Figure 1—figure supplement 3D, the cata-
lytic activity of 1 mM ANGPTL41–159 was similar regardless of the integrity of the disulfide bond. In
conclusion, a covalent oligomer of ANGPTL41–159 is not essential for its catalytic LPL-unfolding activ-
ity in vitro. Nevertheless, we cannot formally exclude the possibility that a non-covalent assembly of
ANGPTL41–159 oligomers participates in LPL unfolding.
Figure 1 continued
Figure supplement 1. Estimating the catalytic efficacy of ANGPTL41–159 on LPL unfolding.
DOI: 10.7554/eLife.20958.003
Figure supplement 2. Dose- and time-dependent inhibition of LPL catalytic activity by ANGPTL41–159.
DOI: 10.7554/eLife.20958.004
Figure supplement 3. Oligomerization status of purified ANGPTL41–159.
DOI: 10.7554/eLife.20958.005
Figure supplement 4. ANGPTL4-mediated inhibition of LPL at 4˚C —impact of deoxycholate (DOC).
DOI: 10.7554/eLife.20958.006
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GPIHBP1 binding mitigates the ANGPTL4-catalyzed inactivation of LPL
The proper expression of GPIHBP1 is critical for shuttling LPL to the capillary lumen, where margin-
ation and lipolytic processing of TRLs occurs (Beigneux et al., 2009a; Davies et al., 2010;
Fong et al., 2016; Goulbourne et al., 2014). Recently, we uncovered a new functionality of
GPIHBP1—stabilizing LPL activity by limiting the spontaneous unfolding rate of LPL´s hydrolase
domain (Mysling et al., 2016). These findings prompted us to ask whether the binding of GPIHBP1
to LPL would also protect LPL from ANGPTL4-catalyzed unfolding. To explore this possibility, we
first incubated 10 mM LPL alone or with 30 mM GPIHBP1 for 2 min at 25˚C; we then added 2 mM
ANGPTL41–159 and incubated the mixture for 10 min. In the absence of GPIHBP1, we observed
87 ± 2% unfolding of LPL versus only 8 ± 2% unfolding in the presence of GPIHBP11–131 (Figure 2A).
Comparable results were obtained with spontaneous unfolding of LPL (Figure 2B). Both the LU
domain and the acidic domain of GPIHBP1 (Figure 2C) were required for protecting LPL against
ANGPTL4; neither 30 mM GPIHBP134–131 nor 30 mM GPIHBP11–33 substantially inhibited ANGPTL4-
catalyzed unfolding of LPL (79 ± 7% and 69 ± 12% unfolding, respectively). A slightly different sce-
nario emerged for spontaneous unfolding of LPL; the acidic domain of GPIHBP1 (GPIHBP11–33) was
nearly as effective as full-length GPIHBP11–131 in protecting LPL from unfolding (Figure 2B). To ana-
lyze this difference in more detail, we tested the potency of a mixture of two GPIHBP1 domains (30
mM GPIHBP11–33and 30 mM GPIHBP134–131) on spontaneous and ANGPTL4-catalyzed LPL unfolding.
The GPIHBP11–33/GPIHBP134–131 mixture was less effective than full-length GPIHBP1 in protecting
LPL from ANGPTL4-mediated unfolding (Figure 2A). In conclusion, it would appear that GPIHBP1´s
acidic domain needs to be tethered to the LU domain to achieve GPIHBP1´s full protective effect
against ANGPTL4-catalyzed LPL unfolding (Figure 2A). A covalent association of the two GPIHBP1
Figure 2. GPIHBP1 binding counteracts ANGPTL4-catalyzed unfolding of LPL. Panel A shows the degree of unfolding of 10 mM LPL incubated for 10
min at 25˚C with 2 mM ANGPTL41–159 alone or in the presence of 30 mM GPIHBP11–131, 30 mM GPIHBP134–131, 30 mM GPIHBP11–33, or a mixture of 30 mM
GPIHBP134–131 and 30 mM GPIHBP11–33 (gray bars). The loss in lipolytic LPL activity on samples treated identically is shown by green bars. These activity
data were normalized relative to the initial LPL activity assuming a spontaneous decay of 15% during the experiment. Panel B shows the degree of
spontaneous unfolding of 10 mM LPL before and after a 45 min incubation at 25˚C either alone or in the presence of 10 mM GPIHBP1 in the same
combinations used in panel A. The relative unfolding of LPL is calculated from the bimodal distribution of the isotope envelopes for peptide 131–165.
Panel C shows a molecular model for GPIHBP1 depicting the intrinsically disordered acidic domain (GPIHBP11–33) and the ordered LU domain
(GPIHBP134–131). The acidic residues in the N-terminal domain are highlighted by sticks as is the Arg33, which is exposed and prone to proteolysis
(Mysling et al., 2016). The attachment site for the membrane anchor is indicated (GPI).
DOI: 10.7554/eLife.20958.007
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domains is less important for reducing the spontaneous unfolding of LPL (Figure 2B). In these stud-
ies, we also analyzed catalytic activity of LPL. The protection provided by the different GPIHBP1 pro-
teins against ANGPTL4-mediated LPL unfolding was accompanied by preserved LPL catalytic activity
towards [3H]triolein substrate hydrolysis (Figure 2A).
To further interrogate the mode of action of ANGPTL4-catalyzed LPL inhibition, we added 300
nM intact GPIHBP1 [12-fold above the KD for the GPIHBP1.LPL interaction (Mysling et al., 2016)] to
LPL (15 nM) that had been partially inactivated—either by incubating the enzyme at 21˚C (spontane-
ous inactivation) or by incubating the enzyme with 7.5 nM ANGPTL4 (catalyzed inactivation). As
shown in Figure 3, adding GPIHBP1 to the partially inactivated LPL protected the remaining LPL
from inactivation, but neither the spontaneously inactivated LPL nor the ANGPTL4-inactivated LPL
was resurrected by GPIHBP1. These findings align with the HDX-MS data (Figure 1C) showing that
both the spontaneous and ANGPTL4-mediated LPL inactivation pathways result in very similar (if not
identical) conformational changes in LPL. Our studies further substantiates that ANGPTL4 catalyzes
LPL unfolding/inactivation in an irreversible manner rather than acting as a noncompetitive and
reversible inhibitor as previously suggested (Lafferty et al., 2013). If ANGPTL4-mediated inactiva-
tion of LPL were to be reversible, we would have expected to find reactivation of LPL during the
incubation with GPIHBP1.
Unfolding properties of ANGPTLE15K
Genetic studies have revealed that a polymorphic variant in ANGPTL4 (ANGPTL4E15K, with a ~3%
prevalence in Caucasians) is associated with lower plasma triglyceride levels and reduced risk of cor-
onary artery disease (Dewey et al., 2016; Helgadottir et al., 2016; Stitziel et al., 2016). We
expressed and purified the coiled-coil domain of ANGPTL4E15K. The kinetic profile of LPL unfolding
with ANGPTL4E15K was more complex and included a time-dependent decline in LPL-unfolding activ-
ity (using conditions in which substrate depletion was not rate-limiting) (Figure 4A). We were able to
take advantage of the linear phases of the progress curves for LPL unfolding to estimate the unfold-
ing efficacy of ANGPTL41–159/E15K. The ANGPTL4 variant resulted in the unfolding of 0.6 ± 0.1 mole-
cules LPL per ANGPTL4 molecule per min (Figure 4B and C), which is only 40% of the activity of
wild-type ANGPTL4 (Figure 4C). We obtained consistent results when measuring LPL activity; the
LPL incubated with ANGPTL41–159/E15K retained 40–50% more catalytic activity than LPL incubated
with wild-type ANGPTL4 (Figure 4D). The LPL unfolding curves (Figure 4A and B) suggested that
ANGPTL41–159/E15K lost activity more rapidly than wild-type ANGPTL4 during the LPL incubation.
Protein dynamics of ANGPTL4
Given the differences in the kinetics of LPL-unfolding catalyzed by ANGPTL4wt and ANGPTL4E15K,
we embarked on determining the intrinsic protein dynamics of the two ANGPTL proteins with HDX-
MS. We incubated 3 mM ANGPTL41–159 in 10 mM Na2HPO4, 150 mM NaCl (pH 7.1) containing 70%
(v/v) D2O for 10, 100, or 1000 s at 25˚C. We recovered 41 peptides from ANGPTL41–159 after on-line
pepsin digestion (corresponding to 95.6% sequence coverage) (Figure 5—figure supplement 1A
and B). As illustrated by the heat maps for deuterium uptake, wild-type ANGPTL41–159 contains two
regions that are less dynamic (residues 19–43 and 85–111). Both sequences are predicted by
PSIPRED to form a-helices (Figure 5A). Of the two a-helices, the N-terminal a-helix of ANGPTL4 is
less stable (i.e., has a greater deuterium uptake). The isotope envelopes reveal that the deuterium
uptake in this particular region occurs via mixed EX1 and EX2 kinetics signifying some degree of
cooperative unfolding (Weis et al., 2006).
A comparison of the kinetics for deuterium uptake into ANGPTL41–159/E15K and ANGPTL41–159/wt
revealed a conspicuous difference: peptides covering residues 19–43 exchanged more rapidly in
ANGPTL41–159/E15K (Figure 5A and C). The increased deuterium incorporation occurs predominantly
via faster EX1 kinetics reflecting an increased propensity for cooperative unfolding of that region.
Given that this region coincides with the predicted N-terminal a-helix in ANGPTL4, it is conceivable
that the Glu-to-Lys substitution in the E15K variant compromises protein stability by reducing the a-
helix propensity of the adjacent C-terminal sequence. Our findings are likely biological relevant, pro-
viding a plausible molecular explanation for the impaired LPL inactivation and lower plasma triglycer-
ide levels in carriers of the E15K polymorphism.
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Figure 3. GPIHBP1 cannot reverse loss of LPL activity after spontaneous or ANGPTL4-catalyzed inactivation. Panel
A shows time-dependent loss of LPL catalytic activity after incubating LPL at 21˚C alone or in the presence of
GPIHBP1. The progressive loss in catalytic activity of LPL (15 nM) during the incubation is shown by red triangles;
the protection provided by a pre-incubation with GPIHBP11–131 (300 nM) is shown by black squares. Adding
GPIHBP11–131 (300 nM) to LPL that was incubated alone for 20 min (green arrow) prevented any further loss of LPL
(green squares). Panel B shows inactivation of LPL catalytic activity by 7.5 nM ANGPTL41–159 (red diamonds). The
inhibition of LPL activity by ANGPTL4 was markedly reduced by the presence of 300 nM GPIHBP11–131 (blue
circles); however, a small amount of ANGPTL4-mediated inhibition probably still persisted during the incubation
with GPIHBP1, given that LPL catalytic activity was greater when LPL was incubated with GPIHBP1 in the absence
of ANGPTL41–159 (black squares). When 300 nM GPIHBP11–131 was added to LPL 10 min after the initiation of
ANGPTL4-mediated LPL inactivation (green arrow), there was no further loss of LPL activity (green circles).
However, the loss of LPL activity that had occurred during the first 10 min of incubation was not reversed (i.e. there
Figure 3 continued on next page
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Unfolding catalyzed by intact ANGPTL3
Sequence alignments of the different ANGPTL proteins implicated in triglyceride metabolism
(ANGPTL3, ANGPTL4, ANGPTL8) reveal strong sequence conservation in the N-terminal region that
is destabilized in ANGPTL4E15K (Figure 6A). Interestingly, this region constitutes a part of the epito-
pes on ANGPTL3 or ANGPTL4 for monoclonal antibodies that mitigate LPL inactivation in vivo
(Lee et al., 2009). In view of these observations, we tested whether purified ANGPTL3 might also
serve as a catalyst for LPL unfolding. We found that ANGPTL3 also accelerates the unfolding of the
catalytic triad peptide leading to inactivation of LPL, but at reduced efficacy compared with equimo-
lar amounts of ANGPTL4 (Figure 6B and C). The ANGPTL3-catalyzed inactivation of LPL is abro-
gated by GPIHBP1 (Figure 6C).
Discussion
The intravascular hydrolysis of triglycerides by LPL is the central event in plasma lipoprotein metabo-
lism, providing fatty acids that are used as fuel in striated muscle and brown adipose tissue or stored
in the form of triglycerides in white adipose tissue. Normally, LPL activity is tightly regulated, facili-
tating the delivery of lipid nutrients according to the metabolic demand of tissues and the physio-
logic state of the organism (e.g., fasting, cold exposure, exercise). One of the most important
mechanisms for regulating LPL activity relies on temporal and spatial repression by the inhibitors
ANGPTL3, ANGPTL4, and ANGPTL8. The physiological importance of these inhibitors has come into
focus as a result of genome-wide association studies and pharmacological and genetic studies in ani-
mal models (Desai et al., 2007; Dewey et al., 2016; Gusarova et al., 2015; Helgadottir et al.,
2016; Wang et al., 2013a). However, uncertainty has persisted regarding the molecular mechanism
(s) by which these inhibitors modulate LPL activity.
In the current study, we used HDX-MS analyses to study the inhibition of LPL by ANGPTL4. Our
studies showed that ANGPTL4 induces a dose- and time-dependent unfolding of LPL´s hydrolase
domain, and that these structural changes are accompanied by a parallel reduction in LPL’s capacity
to hydrolyze a lipid emulsion containing [3H]triolein. Importantly, the unfolding of LPL´s hydrolase
domain occurred with substoichiometric amounts of ANGPTL4. Combined, our data infer that
ANGPTL4 acts by accelerating the spontaneous unfolding of LPL (Mysling et al., 2016). Our data
are closely aligned with and extend the notion that ANGPTL4 acts as an ‘unfolding molecular chap-
erone’ (Sukonina et al., 2006). They are however not compatible with the view that ANGPTL4 act as
a reversible and non-competitive inhibitor of LPL activity (Lafferty et al., 2013). The studies that led
to the latter model involved incubating LPL in the presence of 1–5 mM deoxycholate (DOC), an
anionic detergent that is known to bind to and stabilize LPL activity (Bengtsson and Olivecrona,
1979). When we replicated those experiments in the absence of DOC, we found a time-dependent
inactivation of LPL activity consistent with an irreversible mechanism (Figure 1—figure supplement
4). We suspect that DOC changes the intrinsic dynamics of LPL’s hydrolase domain, preventing it
from visiting unstable conformations. In the absence of DOC, ANGPTL4 may bind transiently to LPL,
stabilize a folding intermediate that ‘guides’ LPL towards irreversible unfolding, and ultimately cause
permanent LPL inactivation. Whether this intermediate is an integrated part of the LPL homodimer
or it represents a dissociated monomer is currently unclear. Importantly, our model for ANGPTL-cat-
alyzed unfolding of LPL involves an ATP-independent mechanism unlike those generally employed
by intracellular unfoldases (Prakash and Matouschek, 2004). Nevertheless, our model is not
completely unprecedented as it bears some resemblance to the oligomerization of a1-antitrypsin
that is catalyzed by a monoclonal antibody raised against its pathogenic (E342K) Z-variant
(Irving et al., 2015).
Several studies have shown that ANGPTL4 undergoes a variable degree of oligomerization at or
close to the cell surface via the formation of intermolecular disulfide bonds between Cys51 and Cys55
in different coiled-coil domains—and that the covalent oligomerization is biologically significant
Figure 3 continued
was no resurrection of ANGPTL4-inactivated LPL). LPL activity measurements were performed in triplicated; data
shown ± SD.
DOI: 10.7554/eLife.20958.008
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Figure 4. Impact of ANGPTL4E15K on LPL unfolding. Panel A shows the time-dependent unfolding of 10 mM LPL in
the presence of 2, 1, and 0.5 mM ANGPTL41–159/E15K, highlighted by black solid lines and the green, red and blue
circles, respectively. For comparison the unfolding mediated by 0.5 mM ANGPTL41–159/wt is shown by the gray solid
line. The hatched line represents spontaneous LPL unfolding. The corresponding data are shown in panel B after
Figure 4 continued on next page
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(Ge et al., 2004a, 2004b; Makoveichuk et al., 2012; Yin et al., 2009). In the current study, we
show that the redox states of Cys51 and Cys55 do not influence ANGPTL4-mediated catalysis of LPL
unfolding. Consistent with our findings, an independent study showed that the LPL inhibitory poten-
tial of ANGPTL4 in vitro was not altered when Cys51 and Cys55 were changed to serine (Shan et al.,
2009). The ability of ANGPTL4—lacking disulfide bonds in the coiled-coil domain—to inactivate LPL
is consistent with recent studies showing that ANGPTL4 can inactivate LPL intracellularly and reduce
its secretion from cells (Dijk et al., 2016). In this compartment ANGPTL4 does not form covalent
oligomers (Makoveichuk et al., 2012). Rather than being important for the catalytic properties of
ANGPTL4, the covalent oligomerization could serve to increase its biological stability and ensure a
proper extracellular partitioning of the coiled-coil domain of ANGPTL4 in vivo (Yin et al., 2009).
LPL-mediated hydrolysis of triglycerides occurs predominantly at discrete foci along the capillary
bed where lipoproteins are sequestered by LPL.GPIHBP1 complexes on the endothelial cell mem-
brane (Fong et al., 2016; Goulbourne et al., 2014). Given that the majority of LPL in the capillaries
is bound to GPIHBP1, as judged with immunohistochemistry, it becomes pertinent to evaluate the
inhibitory property of ANGPTL4 in that context. In an earlier study (Sonnenburg et al., 2009), solu-
ble GPIHBP1, but not heparin, protected LPL‘s esterase activity from ANGPTL4-catalyzed inactiva-
tion. In our current study, we also found that GPIHBP1 protected LPL´s catalytic activity, and this
protection was achieved by blocking ANGPTL4-catalyzed unfolding of LPL´s hydrolase domain (Fig-
ure 2). Noteworthy, full-length GPIHBP1 was required for robust protection of LPL from ANGPTL4;
a mixture of GPIHBP1‘s LU and acidic domains provided only a modest protection. In view of those
observations, we propose a molecular model in which the LU domain of GPIHBP1 secures a tight
binding to the carboxyl-terminal domain of LPL. This assembly allows an optimal positioning of
GPIHBP1‘s intrinsically disordered acidic domain close to the unstable catalytic domain of LPL pro-
tecting it from ANGPTL4-catalyzed unfolding.
One implication of our findings is that only GPIHBP1-bound LPL would be protected from
ANGPTL4 in vivo. We predict that this selectivity is relevant for regulating lipid metabolism in several
different compartments.
First, in the secretory pathway of adipocytes, where GPIHBP1 is absent, we suspect that LPL
would be more susceptible to ANGPTL4-mediated unfolding. Accordingly, recent studies of LPL pro-
duction by mouse primary adipocytes and white adipose tissue explants indicate that ANGPTL4
interacts with LPL in the trans-Golgi network, targeting it for lysosomal degradation (Dijk et al.,
2016). The endoplasmic reticulum has an efficient quality control system that targets thermodynami-
cally unstable proteins for disposal via ERAD (Ellgaard and Helenius, 2003). Emerging evidence
suggests that an equivalent quality control system may also exist in the trans-Golgi network. In Sac-
charomyces cerevisiae, the trafficking receptor Vps10p serves as a protein-folding sensor diverting
misfolded proteins to vacuolar disposal (Hong et al., 1996). One of the Vps10p domain–containing
homologs in mammals, the sorting receptor SorLA, is known for its role in the intracellular trafficking
of amyloid precursor proteins and for its association with neurodegenerative diseases
(Andersen et al., 2016). Interestingly, SorLA is also expressed by adipocytes and myocytes and tar-
gets newly synthesized LPL for degradation in lysosomes (Klinger et al., 2011). One possibility—
which obviously needs experimental testing—is that ANGPTL4-catalyzed unfolding of LPL in the
trans-Golgi network primes an anterograde sorting of SorLA-LPL complexes towards the endolyso-
somal degradation pathway. Such a mechanism might account for the increased LPL secretion from
Angptl4-/- adipocytes compared to wild-type adipocytes (Dijk et al., 2016). In keeping with the lat-
ter idea, we speculate that human adipocytes that express ANGPTL4 E15K polymorphism would
secrete elevated levels of LPL.
Figure 4 continued
subtraction of spontaneous unfolding. The solid black lines show the data used to estimate the unfolding rates
and their hatched extension illustrates nonlinearity at longer incubation times. The unfolding rates of ANGPTL41–
159/E15K (circles) and ANGPTL41–159/wt (squares) are represented by the slopes of the lines in panel C. The
difference in the inhibitory efficacies between ANGPTL41–159/wt (gray bars) and ANGPTL41–159/E15K (red bars) on
LPL-mediated hydrolysis of [3H]triolein is shown in panel D (asterisks represent the individual measuring points).
DOI: 10.7554/eLife.20958.009
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Second, freshly secreted LPL—loosely associated with heparan-sulfate proteoglycans (HSPG) in
the interstitial spaces—would also be prone to inhibition by ANGPTL4 (Olivecrona, 2016). It has
been suggested that this compartment represents the primary target site for ANGPTL4-catalyzed
inactivation of LPL (Nilsson et al., 2012). In this setting, translocation of LPL from the HSPG-bound
reservoir to a GPIHBP1-bound state at the basolateral surface of endothelial cells would alleviate the
inhibitor repression exerted by ANGPTL4. We propose that inhibition of LPL within the interstitial
Figure 5. Protein dynamics of wild-type ANGPTL4 and ANGPTL4 containing the E15K polymorphism. Purified ANGPTL41–159 preparations (wt and
E15K) were diluted to 10 mM with D2O-phosphate buffer at pH 7.1, and hydrogen–deuterium exchange was monitored for 10, 100, and 1000 s at 25˚C.
Panel A provides a heat map of the deuterium uptake values (relative to a fully exchanged control) for peptic peptides from wt and E15K ANGPTL41–159
as assessed by HDX-MS. The relative deuterium uptake values for these peptides are plotted on the primary protein sequence [ranging from blue (no
deuterium uptake) to red (full deuterium uptake)]. The position of the specific epitope 1 (SE1) defined by the neutralizing mAb 14D12 is shown by the
light green cylinder (Desai et al., 2007; Lee et al., 2009), and the sequence representing an active synthetic peptide is shown by the dark green
cylinder (Yau et al., 2009). The secondary structure of ANGPTL4 wt was predicted by PSIPRED (Jones, 1999) and the positions of the two a-helices are
shown by red cylinders. The position of E15K polymorphism is shown by the blue letter. Panel B shows the isotope envelopes recorded for peptide 20–
41 of ANGPTL4 wt and E15K; it shows progressive deuterium uptake as a function of labeling time. Panel C visualizes the differences in the dynamics of
wt and E15K ANGPTL41–159 with a butterfly plot, showing differential deuterium uptake for the two proteins recorded after 10 s (orange), 100 s (red),
and 1000 s (blue). The differential uptake for the full-deuterium exchange controls is shown for comparison (black). Peptides including residues 18–30
are highlighted by the transparent green box. The shaded gray area corresponds to the largest standard deviation in the data sets recorded for each
peptide (triplicates). In panel A, note that the primary sequence starts with a methionine for the bacterial expression, but this is not included in the
peptide numbering. In panel C, the presence of the methionine in a peptic peptide is denoted as +1.
DOI: 10.7554/eLife.20958.010
The following figure supplement is available for figure 5:
Figure supplement 1. Peptide list for pepsin-treated ANGPTL41–159.
DOI: 10.7554/eLife.20958.011
Mysling et al. eLife 2016;5:e20958. DOI: 10.7554/eLife.20958 11 of 18
Research advance Biophysics and Structural Biology Human Biology and Medicine
spaces by locally produced ANGPTL4 is important for regulating the amount of active LPL that actu-
ally reaches the surface of capillaries, thereby serving to match the efficiency of intravascular lipolysis
to the metabolic requirements of nearby parenchymal cells.
Finally, we propose that the resistance of GPIHBP1-bound LPL to ANGPTL4- and ANGPTL3-medi-
ated inhibition serves to focus catalytically active LPL at the luminal surface of capillary endothelial
cells. It is interesting, that human population studies have not uncovered a correlation between
plasma ANGPTL4 levels and triglyceride concentrations (Robciuc et al., 2010; Smart-Halajko et al.,
2010) implying that the regulation of LPL activity in this compartment is far more convoluted. The
low-to-moderate concentrations of circulating ANGPTL4 and ANGPTL3 in the blood are obviously
insufficient to inhibit LPL in the presence of triglyceride-rich lipoproteins (Nilsson et al., 2012). With
that said, it is important to acknowledge that elevated plasma levels of ANGPTL4 protein achieved
by transgenic overexpression or systemic administration clearly breached this protective barrier as
these mice have increased plasma triglyceride levels and vastly reduced post-heparin LPL activity lev-
els (Ko¨ster et al., 2005; Lichtenstein et al., 2007; Nilsson et al., 2012). Similarly, the protection
yielded by GPIHBP1-binding may also not be completely impregnable. With concentrations pre-
dicted to saturate LPL with GPIHBP1 (Figure 2A and Figure 3B), we did observe a minor increase in
LPL unfolding/inactivation in the presence of large amounts of ANGPTL4 in vitro. Intravascular lipoly-
sis is thus a highly tunable biological process where the net activity is critically dependent on a com-
plex interplay between local concentrations of cognate activators and inhibitors and their
partitioning between different compartments. Using selective inhibitor repression to focalize a given
Figure 6. ANGPTL3-catalyzed unfolding of LPL. Panel A shows a sequence alignment of the first 55 residues of fully processed human ANGPTL3,
ANGPTL4, and ANGPTL8. Identical sequences are highlighted by blue letters. The filled red box highlights the two-residue acidic motif at the start of
the N-terminal a-helix, followed by a conserved a-helical region (open box). The two cysteine residues unique to ANGPTL4 are shown in yellow boxes.
Panel B shows the time-dependent unfolding of 10 mM LPL by 1 mM ANGPTL3 (green circles) as defined by the appearance of bimodality in the isotope
envelopes for peptide 131–165. For comparison the unfolding of LPL by 1 mM ANGPTL41–159 is shown as solid (wild-type) and hatched (E15K) gray lines.
Spontaneous unfolding is shown by black triangles. Panel C shows the residual lipolytic activity of 10 mM LPL incubated for 10 min alone or in the
presence of 1 mM ANGPTL3, 1 mM ANGPTL3 and 30 mM GPIHBP1, or 1 mM ANGPTL41–159.
DOI: 10.7554/eLife.20958.012
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biological activity is not uncommon; for example, during fibrinolysis plasmin-bound to its substrate
(polymerized fibrin) escapes inhibition by a2-antiplasmin (Lijnen, 2001).
Genome-wide association studies have shown that the common polymorphic variant ANGPT-
L4E15K (often denoted E40K) is linked to mild hypotriglyceridemia and reduced risk of coronary
artery disease (Dewey et al., 2016; Helgadottir et al., 2016; Stitziel et al., 2016; Yin et al., 2009).
While the impact of ANGPTL4E15K on lipid metabolism in humans is clear, the structure–function
relationship(s) responsible for its reduced biological activity have been unclear. Our studies com-
bined with previously published studies, suggest that the Glu-to-Lys replacement in ANGPTL4
affects two properties. First, the E15K polymorphism reduces the ability of ANGPTL4 to inhibit LPL
in vitro—to the degree that ANGPTL4E15K functions no better than ANGPTL3 (Shan et al., 2009).
With HDX-MS, we found that ANGPTL4E15K and ANGPTL3 catalyze LPL unfolding to a similar
degree (Figure 6). Second, although the E15K polymorphism has no impact on protein synthesis,
secretion, oligomerization, or secretion, it still limits extracellular accumulation of the coiled-coil
domain of ANGPTL4 in cultured cell systems as well as in adenovirus-transfected mice (Yin et al.,
2009). It has been hypothesized that the effects of the E15K polymorphism on plasma triglyceride
levels relate to a short half-life of the ANGPTL4E15K oligomer (Yin et al., 2009). In the current study,
we provide evidence supporting that idea—by showing that the Glu-to-Lys substitution in ANGPTL4
causes protein destabilization via cooperative unfolding of the first a-helix in ANGPTL4´s coiled-coil
domain (Figure 6). Negative charges at the N-terminus of a-helices generally stabilize coiled-coil
domains via electrostatic interactions with the a-helix dipole moment (Johnson et al., 2014;
Kohn et al., 1997). Accordingly, the charge-reversal in ANGPTL4E15K would be expected to lead to
protein destabilization—in agreement with our HDX-MS data (Figure 5). We suspect that this mech-
anism is a contributing factor to the lower half-life of ANGPTL4E15K.
By HDX-MS, we found that ANGPTL3 catalyzed the inactivation of LPL, although markedly less
efficient compared with ANGPTL4 (Figure 6). GPIHBP1-binding also protected LPL from inactivation
by ANGPTL3, suggesting that the mechanism that we proposed for ANGPTL4-mediated LPL inacti-
vation also applies to ANGPTL3. Of note, ANGPTL3, ANGPTL4, and ANGPTL8 all share a two-resi-
due acidic motif in their first a-helix along with a highly conserved GLLQGLG motif (Figure 6A).
Intervention studies with mAbs recognizing this region in ANGPTL3 and ANGPTL4 reduce plasma
triglyceride levels in animal models, emphasizing the functional importance of this region
(Desai et al., 2007; Gusarova et al., 2015). In light of these observations, we suspect that the func-
tion of other ANGPTL proteins would be sensitive to missense mutations that introduce charge
reversals and compromise conformational stability. Thus far, however, mutations comparable to the
E15K substitution in ANGPTL4 have not been reported in ANGPTL3 or ANGPTL8.
Materials and methods
Purified proteins and reagents
A recombinant secreted version of human GPIHBP1 was produced in Drosophila S2-cells (Invitrogen,
CA) as a fusion protein with domain 3 (D3) of human uPAR (Ga˚rdsvoll et al., 2007). For practical
reasons, the recombinant GPIHBP1 was mutated within its N-terminal disordered region
(Arg38fiGly); that amino acid substitution provides a higher purification yield without altering LPL-
binding properties (Mysling et al., 2016). Bovine LPL was purified from fresh bovine milk by hepa-
rin-Sepharose, hydroxyapatite, and Superdex HR200 size-exclusion chromatography (Cheng et al.,
1985). The coiled-coil domain of wild-type human ANGPTL4 (ANGPTLwt) and ANGPTL4E15K (resi-
dues 1–159 with an N-terminal methionine and a C-terminal 6His-tag) was produced in E. coli BL21
(DE3) with a pet29a vector (Robal et al., 2012). Full-length ANGPTL3 produced in HEK293 cells was
purchased from ProSpec (Ness-Ziona, Israel). A synthetic peptide corresponding to residues 1–33 of
human GPIHBP1 was obtained at a purity of >95% from TAG-Copenhagen A/S (Copenhagen,
Denmark).
For HDX-MS experiments, purified ANGPTL41–159 preparations were dialyzed for 18 hr at 4˚C
against 10 mM formic acid (pH 4.1) using 2000 MWCO Slide-A-Lyzer dialysis cassettes (Thermo Sci-
entific). Protein concentrations were determined by absorbance at 280 nm.
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ANGPTL4-mediated unfolding of LPL assessed by pulse-labeling HDX-
MS
To determine the rates of spontaneous and ANGPTL4-catalyzed LPL unfolding, we incubated LPL
alone or in the presence of ANGPTL4. In brief, 10 mM bovine LPL was incubated in 8.8 mM
Na2HPO4, 0.7 mM HCOOH, 150 mM NaCl (pH 6.9) at 25˚C with 300 RPM mixing, either alone or in
the presence of different amounts of ANGPTL41–159/wt (2 mM, 1 mM, 0.5 mM, 0.25 mM) or ANGPTL41–
159/E15K (2 mM, 1 mM, 0.5 mM). Identical volumes were added to ensure identical buffer compositions
with different concentrations of ANGPTL4. Solutions were incubated for 0.5, 2.5, 5, 10, 15, or 30
min. The folding status of LPL was probed by adding D2O-buffer (10 mM Na2HPO4, 150 mM NaCl,
pD 7.4) to 70% (v/v) D2O and allowing hydrogen–deuterium exchange to occur for 10 s before
quenching the exchange reaction by adding 1 vol ice-cold quench buffer (100 mM Na2HPO4, 0.8 M
tris-(2-carboxyethyl) phosphine (TCEP), 2 M urea in H2O, pH 2.5). Quenched samples were incubated
on ice for 2 min to reduce disulfide bonds and were subsequently snap-frozen in liquid N2 and
stored at –80˚C until analysis by MS. Labeling of all individual time points was replicated 2 to 4
times. The degree of unfolding of LPL’s hydrolase domain was estimated by quantifying the bimodal
isotope distribution for the ‘diagnostic’ peptic peptide 131–165, which contains two residues of LPL´
s catalytic triad. This was accomplished by fitting the bimodal isotope envelope to two Gaussian dis-
tributions and comparing the areas of the resultant fits.
Alkylation of cysteines in ANGPTL4wt
To reduce disulfide bonds and alkylate the free thiols in ANGPTL41–159, the pH was adjusted to 6.5
by adding 3 volumes of 100 mM Bis-Tris, pH 6.5. After adding TCEP (10 mM final concentration),
the reduction of disulfide bonds proceeded for 1 hr at room temperature. Subsequently, thiols were
alkylated by adding 0.1 vol of 0.5 M iodoacetamide followed by a 4 hr incubation in the dark at
room temperature. Alkylated samples were dialyzed overnight in 10 mM formic acid (pH 4.1) to
adjust the pH and remove excess TCEP and iodoacetamide.
Impact of GPIHBP1 on ANGPTL4-catalyzed LPL-unfolding
To study the effect of purified GPIHBP1 on the unfolding of LPL by ANGPTL41–159, we first formed
LPL.GPIHBP1 complexes by incubating 11 mM LPL with 33 mM GPIHBP11–131, 33 mM GPIHBP134–131,
33 mM GPIHBP11–33, or a mixture of 33 mM GPIHBP134–131 and 33 mM GPIHBP11–33 for 2 min at
25˚C. LPL (11 mM) without ligands was incubated in parallel. Unfolding was initiated by adding 10%
(v/v) 20 mM ANGPTL41–159 and allowing unfolding to proceed for 10 min in 10 mM Na2HPO4, 0.1
mM HCOOH, and 150 mM NaCl (pH 7.1) at 25˚C. Similar data were recorded for spontaneous
unfolding of 10 mM LPL, except that GPIHBP1 concentrations were reduced to 10 mM and the incu-
bation time was increased to 45 min. Unfolding of LPL´s hydrolase domain was assessed with pulse-
labeling in 70% D2O for 10 s, followed by quenching and reduction on ice for 2 min. Labeling of
each sample was replicated between 3 and 6 times.
Determination of lipase activity
Before measuring lipase activity with Intralipid containing [3H]triolein, we took care to replicate the
conditions used for the HDX-MS experiments (i.e., 10 mM LPL at 25˚C, identical amounts of
ANGPTL4 and GPIHBP1, and identical buffer conditions). The ANGPTL4-induced unfolding of LPL
was quenched by 10-fold dilution in ice-cold 20 mM Tris (pH 8.5) containing 5 mM deoxycholic acid
(DOC) and 0.1 mM sodium dodecyl sulfate (SDS) (DOC/SDS buffer). Lipase activities were deter-
mined by adding 5 ml of LPL (diluted 100-fold in DOC/ SDS buffer) to 195 ml of incubation mixtures
containing Intralipid with incorporated [3H]triolein and with heat-inactivated rat serum as a source of
the activator apolipoprotein C-II (Larsson et al., 2013).
In some experiments, the protective effects of GPIHBP1 on lipase activity, were assessed in 96
well plates where 60 ml of 15 nM LPL in PBS buffer (pH 7.4) containing 0.01% (v/v) of Trition-X100
were pre-incubated in the presence or absence of 7.5 nM ANGPTL4 and 300 nM GPIHBP1 at 21˚C
and shaking at 600 rpm. To determine lipase activity at a given pre-incubation time, 90 ml incubation
mixture containing Intralipid and human serum (as a source of apolipoprotein C-II) were added and
the incubation was continued for 25 min at room temperature. After terminating the reaction by
adding Triton X-100 to a final concentration of 2.5% (v/v), the amount of lipase-generated, non-
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esterified fatty acids (NEFA) were quantified using a NEFA-HR(2) assay according to
the manufacturer’s protocol (Wako Diagnostics). Measurements were performed in triplicates.
Protein dynamics of ANGPTL4 measured by HDX-MS
Labeling with deuterium was initiated by 3.3-fold dilutions of 10 mM ANGPTL41–159/wt or ANGPTL41–
159/E15K (in 10 mM Na2HPO4, 150 mM NaCl) into the equivalent deuterated buffer (pD 7.4), yielding
the following exchange conditions: 70% (v/v) D2O, pH 7.1 (as measured with identical solutions pre-
pared from protiated reagents). Solvent exchange was allowed to proceed for 10, 100 or 1000 s at
25˚C with 300 RPM mixing. At the indicated time intervals, the exchange reaction was quenched
with 1 vol ice-cold quench buffer and protein disulfides reduced for 2 min on ice. On-line digestion
with pepsin yielded 41 peptides shared by ANGPTL4wt and ANGPTL4E15K, providing 96% sequence
coverage. Full deuteration controls were prepared by allowing LPL samples to exchange in the same
buffer for 48 or 72 hr at 37˚C. No additional deuterium uptake could be observed after 48 hr.
MS analysis of HDX-labeled samples
Deuterium incorporations into proteins was determined after on-line pepsin digestion of the samples
with an HDX-modified reversed-phased chromatographic system coupled to a Synapt G2 electro-
spray ionization mass spectrometer (Waters, Milford, MA) (Mysling et al., 2016).
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